Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information It has been concluded that this licence extension will be incorporated into the Multi-Technology Appraisal of Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]. For more information on ID3834, please email
ID number 10767

Project Team

Project lead Abigail Stephens

Email enquiries

For further information on how we select topics for development, please see our page about topic selection